Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
AssigneeFred Hutchinson Cancer Research Center
InventorsSusanna Carolina Berger, Stanley R. Riddell
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for boosting, augmenting or enhancing the efficacy of the adoptive cellular immunotherapy by using modified T cells expressing an antigen binding protein in conjunction with modified cells (such as hematopoietic progenitor cells, modified human immune system cells or a combination thereof) expressing the antigen specifically bound by the antigen binding protein of the modified T cells.
Claims75
A method for improving adoptive cellular immunotherapy, comprising:
- (a) administering to a subject an effective amount of a population of modified human T cells comprising a nucleic acid molecule that encodes an antigen binding protein, wherein the antigen binding protein comprises a hydrophobic portion disposed between an extracellular binding component and an intracellular effector component;
- and
- (b) administering to the subject an effective amount of a population of modified human hematopoietic progenitor cells, modified human immune system cells or a combination thereof comprising a nucleic acid molecule that encodes the antigen, wherein the extracellular binding component of the antigen binding protein from the modified human T cells of step (a) is specific for the antigen encoded by the population of modified cells of this step (b);
- thereby boosting, augmenting or enhancing the efficacy of the adoptive cellular immunotherapy.
A method for treating a disease in a subject, comprising:
- (a) administering to a subject an effective amount of a population of modified human T cells comprising a nucleic acid molecule that encodes an antigen binding protein, wherein the antigen binding protein comprises a hydrophobic portion disposed between an extracellular binding component and an intracellular effector component;
- (b) administering to the subject an effective amount of a population of modified human hematopoietic progenitor cells, modified human immune system cells or a combination thereof comprising a nucleic acid molecule that encodes the antigen, wherein the extracellular binding component of the antigen binding protein from the modified human T cells of step (a) is specific for the antigen encoded by the population of modified cells of this step (b);
- and
- (c) optionally repeating step (a), step (b) or both steps (a) and (b);
- thereby treating disease by adoptive cellular immunotherapy.
A method for treating a hyperproliferative disease, comprising:
- (a) administering to a subject an effective amount of a population of modified human T cells comprising a nucleic acid molecule that encodes an antigen binding protein, wherein the antigen binding protein comprises a hydrophobic portion disposed between an extracellular binding component and an intracellular effector component;
- (b) administering to the subject an effective amount of a population of modified human hematopoietic progenitor cells, modified human immune system cells or a combination thereof comprising a nucleic acid molecule that encodes the antigen, wherein the extracellular binding component of the antigen binding protein from the modified human T cells of step (a) is specific for the antigen encoded by the population of modified cells of this step (b);
- and
- (c) optionally repeating step (a), step (b) or both steps (a) and (b);
- thereby treating the hyperproliferative disease.
An adoptive cellular immunotherapy composition, comprising a population of modified human hematopoietic progenitor cells, modified human immune system cells or a combination thereof, wherein a first population of modified cells are T cells comprising a nucleic acid molecule that encodes an antigen binding protein, and a second population of modified cells comprising a nucleic acid molecule that encodes the antigen,
- wherein the antigen binding protein comprises a hydrophobic portion disposed between an extracellular binding component and an intracellular effector component, and
- wherein the extracellular binding component is specific for the antigen encoded by the second population of modified cells.
Dependencies are inferred from the claim text.